Targeting Early Activated T cells for Adoptive Therapy
Targeting Early Activated T cells for Adoptive Therapy
批准号:
7729347
负责人:
DAVID J COLE
金额:
$25.93万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-01 至 2011-08-31
关键词:
AddressAffectAntigen PresentationAntigen-Presenting CellsAntigensAvidityCD8B1 geneCell CommunicationCell SurvivalCellsClinicalCyclophosphamideDendritic CellsDevelopmentEffectivenessEnvironmentFrequenciesFunding MechanismsGenerationsGoalsImmunotherapyIn VitroInterleukin-12LengthLymphocyte Homing ReceptorsLymphoidLymphopeniaMAP Kinase Signaling PathwaysMemoryModelingPatientsPhagocytosisPhasePhenotypeProtocols documentationSignal TransductionStagingT memory cellT-LymphocyteTelomeraseTestingTitrationsTumor ImmunityVaccinesbasecancer therapyconditioningdesignearly experienceexperiencein vivoinsightinterestlymph nodesmelanomanovelperipheral bloodpreconditioningresponsetraffickingtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Effective anti-tumor immunity requires the generation and persistence of functional, high avidity tumor-specific effector and memory T cells. Among the critical factors that often control this response is the activation/differentiation state of the relevant effector T-cells. We have made the singular observation that IL- 12 conditioning during in vitro priming is able to promote the acquisition of a central memory (Tcm) like phenotype in antigen-specific T cells. These “early activated” T (TEA) cells are characterized by increased expression of lymph node (LN) homing receptors, robust proliferation in vitro, an augmented survival, and increased anti-tumor activity in vivo. We have also recently observed that cyclophosphamide (CTX) preconditioning induces expansion of immature DCs mainly in the peripheral blood during the rebound phase which is associated with highly effective anti-tumor responses in vivo. With an interest in capitalizing on the combined potential of these observations, we hypothesize that the enhanced survival and function of IL- 12 pre-conditioned TEA cells will result in the generation of more effective anti-tumor immunity when combined with a surging frequency of circulating DCs. To test this hypothesis we propose to define how IL-12 pre-conditioning enhances T-cell survival and function (looking at co-stimulation signature, survival signaling, and impact on functional avidity) and define the TEA cell response to antigen presentation in a DC rich environment (looking specifically at the contribution of secondary lymphoid compartments. The ability to understand and harness the combined potential of early activated T cell generation and robust circulating DC induction could serve to synergistically augment in the generation of an effective anti-tumor response in vivo. The two year ARRA funding mechanism will allow us to address the first aspect of this goal by defining how IL-12 conditioning enhances antigen experienced T-cell survival and function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TCR Transduced CD8+ T Cells for Adoptive Immunotherapy
-
批准号:8555357
-
项目类别:
-
资助金额:$27.95万
-
财政年份:2011
-
负责人:DAVID J COLE
-
依托单位:
Clinical Trials using TCR Transduced T Cells for Adoptive Immunotherapy
-
批准号:8555361
-
项目类别:
-
资助金额:$69.33万
-
财政年份:2011
-
负责人:DAVID J COLE
-
依托单位:
CLINICAL TRIAL: ACTIVE IMMUNOTHERAPY AFTER RESECTION OF HEPATIC METASTASES OF CO
-
批准号:7719587
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2008
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7894765
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7667203
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7305271
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7497986
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:8118020
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION
-
批准号:6633528
-
项目类别:
-
资助金额:$22.52万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION
-
批准号:6263186
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7392294
-
项目类别:
-
资助金额:$24.92万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Targeting Early Activated T cells for Adoptive Therapy
-
批准号:7876822
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION
-
批准号:6514208
-
项目类别:
-
资助金额:$22.52万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7087944
-
项目类别:
-
资助金额:$25.66万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:6913665
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7226764
-
项目类别:
-
资助金额:$24.92万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7226938
-
项目类别:
-
资助金额:$12.58万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7425503
-
项目类别:
-
资助金额:$12.64万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:6821679
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7119390
-
项目类别:
-
资助金额:$11.36万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
海外基金